Park and his fellows designed a cyclized oligopeptide against DKK1-low density lipoprotein receptor-related protein (LRP) 5/6 interaction and found reduced tumor burden in results after treatment with it, as a high level of DKK1 often results in osteolytic bone lesions in multiple myeloma models [91]. The gene discussed is DKK1; the disease is plasma cell myeloma.